Compare DFH & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DFH | PRCT |
|---|---|---|
| Founded | 2008 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2020 | 2021 |
| Metric | DFH | PRCT |
|---|---|---|
| Price | $11.28 | $17.30 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 11 |
| Target Price | $26.00 | ★ $35.44 |
| AVG Volume (30 Days) | 891.1K | ★ 1.2M |
| Earning Date | 05-12-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1.71 |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $4,322,848,000.00 | $308,054,000.00 |
| Revenue This Year | $0.81 | $31.34 |
| Revenue Next Year | $7.82 | $24.52 |
| P/E Ratio | $30.47 | ★ N/A |
| Revenue Growth | N/A | ★ 37.22 |
| 52 Week Low | $10.87 | $16.67 |
| 52 Week High | $27.20 | $38.11 |
| Indicator | DFH | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 36.33 | 33.27 |
| Support Level | N/A | $16.89 |
| Resistance Level | $16.47 | $29.27 |
| Average True Range (ATR) | 0.69 | 0.94 |
| MACD | -0.08 | -0.35 |
| Stochastic Oscillator | 12.05 | 4.26 |
Dream Finders Homes Inc designs, builds and sells homes in markets throughout the United States. The company's primary focus is on constructing and selling single-family homes across entry-level, first-time move-up, second-time move-up, and active adult markets. Its homebuilding operations are organized into four reportable segments: Southeast, Mid-Atlantic, Midwest, and Financial Services. It generates the maximum of its revenue from the Midwest segment.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.